save and improve the lives of patients
learn moreawareness
There is an outstanding need for new treatments for bladder cancer. We are proud to support the Bladder Cancer Advocacy Network in building awareness of the need for a cure.
results
Our preliminary Phase 3 data show Vicinium is very well-tolerated and with demonstrated efficacy in patients with high-grade NMIBC.
innovation
Our CSO will give a featured talk with updated data from our VISTA Trial at the Antibody Engineering and Therapeutics Conference in San Diego in December. We look forward to hearing the discussions around innovation in our industry.
bringing new hope for treating bladder cancer
Vicinium is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC). To-date, Vicinium has been well-tolerated in treated patients and has demonstrated efficacy, resulting in a 15% complete response rate for patients with 12-month follow-ups in our ongoing Phase 3 trial.
LEARN MORE
BLADDER CANCER
6th
most common cancer
72
average age of diagnosis
80,000+
new cases each year in the U.S.
$4 billion
annual costs
what we’ve been up to
12/27/18
Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer
12/03/18
Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer
11/08/18
Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts
RENEW LIFE
change lives with us
We are a group of motivated individuals who are committed to changing lives for the better. Learn more about our open positions and how you can renew life with us.
learn more